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Abstract
Background: Complications after major surgery are a significant cause of morbidity and mortality. Neck dissection
is one of the most commonly performed major operations in Head and Neck Surgical Oncology. Significant surgical
complications occur in approximately 10–20% of all patients, increasing to 40% in patients who have had previous
treatment to the area or have multiple co-morbidities and/or polypharmacy.
Current evidence suggests that fibrin sealants (FS) may have potential clinical advantages in Head and Neck Surgery
through the reduction of complications, volume of wound drainage and retention time of the drains. However, a
paucity of high-quality trial-based evidence means that a surgical trial to determine the effectiveness of FS in
reducing the rate and severity of complications in patients undergoing lateral neck dissection is warranted. The
DEFeND randomised external pilot trial will address critical questions on how well key components of the proposed
study design work together as well as the feasibility of a future phase III trial.
Methods: The study design that is being piloted is that of a two-arm, parallel group, superiority trial with block
randomisation in a 1:1 allocation ratio. The interventional arm will constitute the application of FS (Artiss, Baxter
Healthcare Ltd.) to the surgical wound following completion of a neck dissection procedure, in addition to standard
of care (SOC). The control arm will constitute SOC alone. Eligible patients will include patients who require a lateral
neck dissection with a minimum of three cervical nodal levels. Patients who require bilateral neck procedures or
undergoing immediate reconstruction with free or regional flaps will be excluded. The outcomes being assessed
will be recruitment rate, screened to randomisation rate, fidelity of blinding process using blinding indices, number
of missing or incomplete data entries, number of protocol deviations and number of losses to follow-up. Suitability
of the outcome measures proposed for the future phase III trial will also be assessed.
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Discussion: The anticipated challenges for this study will be recruitment, complexity of the intervention and
adherence to the protocol. The outcomes will inform the design, feasibility and conduct of a future phase III
surgical trial.
Trial registration: First participant randomised: November 06, 2018; UKCRN Portfolio ID: 37896; ISRCTN99181100.
Keywords: Fibrin tissue adhesives, Neck dissection, Postoperative complications, Clinical trial protocol, Pilot studies,
Surgical oncology
Introduction
Background and rationale
Complications after major surgery are a significant cause
of morbidity and mortality and have been shown to have
a negative impact on long-term quality of life and
psychosocial well-being [1, 2]. In surgical oncology, com-
plications can also delay adjuvant treatment (e.g. radio-
therapy) which is known to adversely affect survival [3].
Following resection of the primary tumour, neck dissec-
tion is the most commonly performed ‘major operation’
in Head and Neck Surgical Oncology. Hospital Episode
Statistics (HES) suggest that approximately 1500 neck
dissections are performed within the National Health
Service (NHS) in England annually [4]. Significant surgi-
cal complications occur in approximately 10–20% of
patients undergoing neck dissection [5, 6]. Such risks
increase to 40% in patients who have had previous
chemo-radiotherapy to the area or when operating on
higher risk patients of increasing age, with multiple co-
morbidities and/or polypharmacy [7, 8]. Common
surgical complications include haematoma formation,
surgical site infection, wound breakdown/dehiscence
and fistula formation. Management of these complica-
tions is frequently painful, invasive and may involve
return(s) to theatre. This inevitably delays recovery,
which in turn may result in prolonged hospital stay and
immobility; both of which are known risk factors for
additional complications such as lower respiratory tract
infections and venous thromboembolism.
The direct impact on patients of complications follow-
ing neck dissection has been borne out by a ‘core infor-
mation set’ for informed consent to surgery for oral or
oropharyngeal cancer [9]. Using the Delphi method, this
study found details of major or common complications
including pain, swelling and bleeding that may require a
return to the operating theatre; the likelihood of wound
problems; and details of drips, drains and tubes were im-
portant to both patients and healthcare professionals
alike [9]. Patient opinion is further supported by robust
data from a meta-analysis on the use of surgical drains
in thyroid surgery demonstrating that they (drains) in-
creased both post-operative pain and infection rates
[10]. Clearly drains serve an important role in preventing
potentially life-threatening complications due to neck
swelling; however, reduction in the duration of their use,
through early safe removal, and in reduction of wound-
related complications will clearly translate to significant
patient benefit in the immediate post-operative period.
A recent systematic review and meta-analysis on the
use of fibrin sealants (FS) in Head and Neck Surgery
found potential clinical advantages to both patients and
healthcare organisations through reduction in complica-
tions and volume of wound drainage, thereby minimis-
ing the retention time of the drains [11]. FS are
commercially available, US Food and Drug Administra-
tion (FDA) approved, products that have been investi-
gated broadly across several areas of surgery [12]. FS is
applied to the raw surfaces of the surgical wound prior
to closure providing an adjunct to haemostasis. The
mechanism of action is through replication of the final
stages of the clotting cascade through which thrombin
cleaves fibrinogen to form a fibrin clot. The subsequent
clot effectively seals small vessels and occludes cavity
dead space by adhering the wound surfaces; both essen-
tial steps in avoiding haematoma formation that may
compromise surgical site healing. Results of previous in-
vestigations of FS effectiveness in surgery have been
variable and have frequently been unduly influenced by
poor study design.
The key relevant findings of the systematic review and
meta-analysis on the use of FS in Head and Neck
Surgery were as follows [11]:
 There is a paucity of high-quality trials on the use of
FS in Head and Neck Surgery.
 There was a tendency for FS to reduce drainage
volume.
 There was a suggestion that FS may reduce ‘mean
retention time of drains’ and ‘hospital length of stay’
but these were not statistically significant.
 Whilst not reaching statistical significance, FS may
be protective against complications compared to
standard of care. The benefit of FS was greater with
regard to haematoma/seroma formation.
 Patients at high risk of complications (e.g.
anticoagulation and previous surgery or
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radiotherapy) were excluded from all studies
analysed, leaving the effects of FS in populations
most likely to benefit not assessed.
 The role of FS in lateral neck dissection is an area of
need for further studies. Only 2 trials have been
performed so far that have randomised 78 patients
between them [13, 14]. Their inclusion criteria and
findings varied greatly and substantial statistical
heterogeneity impaired conclusive results in the
meta-analysis.
Drawing upon the available evidence and apparent
surgical equipoise with respect to FS usage, it is felt that
a surgical trial to determine the effectiveness of FS in re-
ducing the rate and severity of complications in patients
undergoing lateral neck dissection is warranted. This
important clinical question is framed by patient opinion
and guided by a clinical desire to reduce morbidity.
However, given the difficulties in the delivery of Head
and Neck Surgical Trials [15], this external pilot study
will be used to answer critical questions on how well key
components of the proposed study design work together
as well as the feasibility of the future trial.
Objectives
The key objectives of this randomised external pilot
study are to assess the following points:
 Whether patients can be recruited and retained at a
rate of approximately 4 patients per month across
the 2 centres.
 Determining the effectiveness of the blinding
strategy using blinding indices.
 Ensuring the administrative processes of
randomisation, allocation concealment and data
management work well within the study.
 Assess adherence to the conditions of the protocol.
 Provide evidence to inform the sample size
calculation for the future phase III multicentre
randomised trial
Methods/design
Trial design
This is a randomised external pilot trial set within two
UK hospitals offering tertiary head and neck surgery
services (Aintree University Hospital NHS Foundation
Trust & Queen Victoria Hospital NHS Foundation
Trust). Both institutions serve a large population with a
mix of both urban and rural communities. Aintree
University Hospital treats a population that includes the
most deprived 10% of the UK [16]. The target popula-
tion for this study is patients that are due to undergo
lateral neck dissection as part of their treatment for
Head & Neck Cancer.
The study design that is being piloted is that of a
two-arm, parallel group, superiority trial with block
randomisation in a 1:1 allocation ratio. The interven-
tional arm will constitute the application of FS (Artiss,
Baxter Healthcare Ltd.) to the surgical wound in
addition to standard of care (SOC), and the control
arm will constitute SOC alone. For the purposes of this
study, SOC constitutes the surgeon performing the
neck dissection as they normally would and establishing
complete haemostasis. Patients in both arms will have a
single surgical drain placed and the wound closed with
resorbable sutures across the platysma layer and metal
clips to close the skin. The use of FS or any other
adjunct to haemostasis in neck dissection is not a com-
mon place within the UK. For this reason, the selection
of SOC as the comparator is justified. The Consolidated
Standards of Reporting Trials (CONSORT) diagram is
shown in Fig. 1.
The protocol has been prepared in line with the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines. The SPIRIT Figure shows the
different data collection steps of the pilot trial (Table 1);
a completed SPIRIT checklist is available as an add-
itional file (Additional file 1).
Trial registration and governance
The DEFeND study was prospectively registered with
the ISRCTN registry. ISRCTN99181100 was assigned
on 16 May 2018. DEFeND is also registered on the UK
Clinical Research Network (UKCRN) study portfolio
(Protocol Number: 37896). The University of Liverpool
is the sole sponsor for this study (sponsor@liverpool.a-
c.uk) and has responsibility for trial oversight, indem-
nity, monitoring trial conduct and governance. All
items from the World Health Organization Trial Regis-
tration Data Set can be found at https://doi.org/10.
1186/ISRCTN99181100.
The funder and sponsor have no role in the study de-
sign, data collection, trial management, analysis of re-
sults or dissemination. The Research Ethics Committee
(REC) agreed that an Independent Data Monitoring and
Safety Committee is unnecessary. A Trial Management
Group monitors progress approximately monthly. The
Trial Steering Committee (TSC) will be convened at the
start, mid-point and end of recruitment.
Eligibility criteria
Inclusion criteria:
• Patients due to undergo lateral neck dissection
• Neck dissection to include a minimum of 3 levels [17]
• Patients who have the capacity to consent
Exclusion criteria:
• Age < 18 years
• Bilateral neck dissection
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• Presence of a vascular pedicle for reconstruction
• Pregnancy or breastfeeding
• Known hypersensitivity reaction to aprotinin
• Previous exposure to FS within 6 months
• Known allergy to dairy products
Storage, preparation and administration of fibrin sealant
(FS)
The DEFeND study will use the 2-ml pre-filled double-
chamber syringe preparation of “Artiss” FS manufactured
by Baxter Healthcare LTD. Artiss has a shelf life of 2 years
and should be stored in its protective packaging and trans-
ported in a frozen state at less than – 20 oC [18].
The “Quick thawing” technique, as described by the
manufacturer, will be used to prepare the FS for use.
Quick thawing is done by placing the FS in a sterile
water bath at 33 °C to a maximum of 37 °C for 5 min.
An infrared thermometer is used to check the water
temperature prior to immersing the FS. Once thawed,
the FS may be stored at 33–37 °C for a maximum of 4 h.
Inspection of both chambers after thawing should reveal
clear or slightly opalescent viscous liquids. Solutions that
Fig. 1 Study flow diagram (CONSORT diagram)
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Table 1 Schedule of assessments (SPIRIT figure)
Procedures Head
and
Neck
Clinic/MDT
Screening Pre-operative
assessment
Baseline* Day of
surgery
(day 0)
Follow-up schedule Premature
discontinuationDaily
in-patient
assessment
Follow-up
1 (days
7–14)
Follow-up
unscheduled
Follow-up
2 (days
28–42)
Identify potential
participant
X X
Approach potential
participant to discuss
study
X X
Medical history X
Physical examination X
Assessment of
eligibility criteria
X
Review of
concomitant
anticoagulant
medications
X X X X X X X X X
Review of previous
treatment to the
ipsilateral neck
X
Demographic
assessment
X
Signed consent form X
Randomisation X
Assessment of patient-reported outcome measures
Neck pain (VAS) X X X X X X
Neck Dissection
Impairment Index
(NDII)
X X X
Wound Healing
Questionnaire
(WHQ)
X X
Surgical protocol
Neck dissection
surgery
X
Allocation revealed
at point of wound
closure
X
Prepare and
administer ARTISS
(interventional arm
only)
X
Assessment of clinical outcome measures
Assessment of AEs
(Clavien-Dindo)
X X X X X X
Wound drainage
volume (ml)
X
Wound drain
removal
X
Hospital discharge X
Assessment of pilot study outcomes
Assessment of
blinding strategy
X X
Assessment of
minimal clinically
X X
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are cloudy/discoloured, contain deposits/particulate mat-
ter or solidified should be discarded [18].
The FS is delivered into the wound as a fine spray
driven by medical grade air. The “EasySpray” pressure
regulator device is setup as per the manufacturer’s in-
structions (Baxter Healthcare LTD) and the spray pres-
sure set to 1.5 bar. The scrub practitioner uses the
Sprayset tubing to attach the FS syringe to the EasySpray
pressure regulator. Precise details on how this is done
can be found on the manufacturer’s website (http://
www.baxterspraysafety.com/uk.html).
The administration of FS requires at least 3 people in-
cluding a scrub practitioner, assistant and surgeon.
While the FS is being thawed, the surgeon should irri-
gate the wound with 100 ml of sterile normal saline, dry
the wound with sterile gauze swabs, secure the surgical
drain and place several resorbable parachute sutures (4–
6) across the platysma layer. These sutures should be
loosely clipped and not tied to ensure good access to the
wound. The drain should be held temporarily outside of
the wound to ensure the perforations are not occluded
by the FS. The prepared Sprayset should not be held any
closer than 10 cm to the wound to avoid the risk of air
embolism. Once the administration of FS has com-
menced, the surgeon has 60 s to deliver up to 2 ml and
manipulate the skin flaps into position prior to polymer-
isation. It is therefore important to strictly adhere to the
time using a stopwatch. The assistant should retract any
structures (e.g. sternocleidomastoid muscle) to ensure
the surgeon can reach sheltered areas and administer
the FS evenly in a thin layer across the entirety of the
wound. Once the administration is complete, the drain
and skin flaps are repositioned and even pressure ap-
plied to the wound (using a large rolled-up gauze swab)
while the surgeon ties off all of the parachute sutures. It
is very important that the surgeon does not lift the skin
edges up while tying the sutures as this may break any
adhesive bond between tissue layers. The surgical vac-
uum drain should then be activated, and the assistant
should maintain pressure on the neck for a full 3 min.
After 3 min, clips/staples are used to close the skin
edges. When spraying the FS, changes in blood pressure,
pulse, oxygen saturation and end-tidal CO2 should be
monitored because of the possibility of air embolism.
Outcomes
The proposed outcome measures for this study can be
divided into those that are specific to the pilot study and
those informing any future phase III trial seeking to de-
termine the effectiveness of FS in neck dissection. As
this is a pilot study, formal assessment of efficacy, cost
or safety across treatment arms will not be made.
The outcomes for the pilot study include the following:
 Proportion of eligible patients recruited to the study,
calculated as the screened to randomisation rate.
 Reasons for failure to screen potentially eligible
patients.
 Recruitment rate measured as the number of
patients randomised each month.
 Reasons for failure to randomise.
 Reasons for failure to reveal allocation at a specific
time point during surgery.
 Fidelity of the blinding process (both patients and
outcome assessors) as detected by blinding indices.
 Accuracy of data recording, summarised by the
number of key data items with missing/incomplete
data entries.
 Number of patients lost to follow-up.
 Protocol adherence, measured by the number of
major/minor protocol deviations observed through
the study.
Table 1 Schedule of assessments (SPIRIT figure) (Continued)
Procedures Head
and
Neck
Clinic/MDT
Screening Pre-operative
assessment
Baseline* Day of
surgery
(day 0)
Follow-up schedule Premature
discontinuationDaily
in-patient
assessment
Follow-up
1 (days
7–14)
Follow-up
unscheduled
Follow-up
2 (days
28–42)
important
Difference
Laboratory tests
Full blood count** X
INR & APTT X
Pregnancy test
(women of
childbearing age)
X
Histological lymph
node yield
X
VAS visual analogue scale, INR international normalized ratio, APTT activated partial thromboplastin time
*At baseline, all procedures should be done before study intervention
**Full Blood Count must include haemoglobin concentration, platelet count and white cell count
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 Determining the minimal clinically important
difference (MCID) in clinical endpoints by
questioning recruited patients and recruiting
clinicians.
The clinical outcomes to inform a future phase III trial
include the following:
 Clavien-Dindo classification of surgical
complications [19].
 Twice daily wound drainage volume (ml).
 Time (hours) for daily wound drainage volume to
reach < 1.25 ml/h.
 Time (hours) to drain removal (as dictated by
drainage volume).
 Total wound drainage volume (ml).
 Time (hours) to be declared medically fit for
hospital discharge and time (hours) to actual
hospital discharge.
 Incremental cost-effectiveness ratio.
Patients reported outcomes to inform the future phase
III trial include the following:
 Neck Dissection Impairment Index (NDII). This is a
procedure-specific patient-reported outcome meas-
ure [20].
 Daily patient-reported pain score using visual
analogue scale (VAS).
 Wound Healing Questionnaire (WHQ). This is a
questionnaire currently in the process of validation
to assess wound healing after surgery [21].
Clavien-Dindo classification of surgical complications
The Clavien-Dindo classification is a widely accepted
tool to grade the severity of surgical complications
(Table 2) [19]. Because it is a generic classification, grad-
ing can be open to interpretation when applying it to
complications specific to Head and Neck Surgery. For
example, Monteiro et al. found that there was imperfect
inter-observer reliability in scenarios where patients
underwent a surgical procedure that did not require
returning to the operating theatre [22]. To avoid this
issue within the context of the DEFeND study, the sever-
ity of common/established complications associated with
neck dissection has been graded to conform to the
Clavien-Dindo classification (Table 3). An assessment of
complications using the Clavien-Dindo classification will
be carried out at every patient encounter after surgery,
i.e. every day of the patient’s hospital stay and at subse-
quent scheduled and unscheduled follow-up visits.
NDII
The NDII is a procedure-specific health-related quality
of life (HRQoL) assessment tool. The tool is validated
for use in patients who have undergone selective or
modified radical neck dissection [20]. Patients will
undertake a baseline NDII pre-operatively and at follow-
up visit 2 (4–6 weeks). Although the NDII is not
validated for use 4–6 weeks after surgery, there is
evidence that the NDII score at this early juncture is
representative of longer-term HRQoL [23].
WHQ
The WHQ has been developed and validated for use in
the Bluebelle study; a feasibility study of different wound
dressing strategies for the prevention of surgical site in-
fection in elective and unplanned abdominal surgery
[21]. Currently, the WHQ has not been validated for use
in Head and Neck Surgery. Patients recruited to the DE-
FeND study will complete the WHQ at follow-up visit 2
(4–6 weeks). Blinded clinicians will assess the wound
Table 2 Clavien-Dindo classification of surgical complications [19]
Grade of
complication
Definition
Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic
and radiological intervention. Acceptable therapeutic regimens are drugs such as antiemetics, analgesia, diuretics and
electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside.
Grade II Requiring pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and
total parenteral nutrition are also included.
Grade III Requiring surgical, endoscopic or radiological intervention.
Grade III-a Intervention NOT under general anaesthesia
Grade III-b Intervention under general anaesthesia
Grade IV Life-threatening complication requiring HDU/ICU management
Grade IV-a Single organ dysfunction (including dialysis)
Grade IV-b Multi-organ dysfunction
Grade V Death
HDU high dependency unit, ICU intensive care unit
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Table 3 Common head and neck/general complications conformed to the Clavien-Dindo classification
Post-operative complication Description of severity Clavien-Dindo grade
Neck wound infection Localised and superficial to platysma, e.g. stitch abscess I
Spreading cellulitis or superficial wound infection with no underlying
collection treated with antibiotics
II
Collection deep to platysma requiring drainage (not under GA) IIIa
Collection deep to platysma requiring drainage (under GA) IIIb
Large collection with organ and/or life-threatening sequelae (i.e. airway ob-
struction, severe sepsis, septic shock)
IV (a or b depending on
organ dysfunction)
Other surgical site infection Localised infection requiring topical or non-invasive treatment I
Infection requiring treatment with antibiotics only II
Collection requiring drainage (not under GA) IIIa
Collection requiring drainage (under GA) IIIb
Large collection with organ and/or life-threatening sequelae (i.e. airway ob-
struction, severe sepsis, septic shock)
IV (a or b depending on
organ dysfunction
Bleeding/haematoma Haematoma not requiring drainage or suitable for simple aspiration with a
needle (not radiologically guided)
I
Need for blood transfusion II
Requiring drainage (not under GA). Includes radiologically guided aspiration/
drainage
IIIa
Requiring drainage or return to theatre for haemostasis (under GA) IIIb
Haematoma/haemorrhage sufficiently large to obstruct airway or cause
hypovolaemic shock
IV (a or b depending on
organ dysfunction)
Chyle leak Low output leak (< 500ml/24 h) suitable for low-fat diet and compression
only
I
Requirement for pharmacological management including total parenteral
nutrition
II
Radiologically guided occlusion IIIa
Return to theatre for the procedure under GA IIIb
Evidence of end-organ dysfunction IV (a or b depending on
organ dysfunction)
Wound breakdown Superficial skin dehiscence (platysma layer intact) managed with dressings I
Small fistula managed by an enteral tube or parenteral nutrition only II
Deep dehiscence (through platysma layer) or fistula managed with procedure
not under GA
IIIa
Deep dehiscence (through platysma layer) or fistula managed with the
procedure under GA
IIIb
Evidence of end-organ dysfunction IV (a or b depending on
organ dysfunction)
Seroma/sialocele Small collection not requiring drainage or suitable for aspiration with a
needle (not radiologically guided)
I
Salivary fistula managed medically (e.g. anticholinergic) II
Requiring drainage (not under GA). Includes radiologically guided aspiration/
drainage
IIIa
Requiring re-exploration and/or drainage (under GA) IIIb
Large collection obstructing airway IVa
Hypersensitivity Mild reaction not requiring treatment I
Mild/moderate/severe reaction treated with medication (e.g. antihistamine
and/or steroid and/or adrenaline)
II
Anaphylactic shock IV (a or b depending on
organ dysfunction)
Air embolism By definition clinically evident air embolism results in cardiorespiratory IVb
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using the Centres for Disease Control and Prevention
(CDC) criteria of surgical site infection. It is expected
that this data will contribute to the validation process.
Health economics
The health economic (HE) assessment of using FS will
be piloted using the ‘incremental cost-effectiveness ratio’
(ICER). This will calculate the average incremental cost
associated with each surgical complication prevented
when compared to SOC. This will be calculated using
the following equation: ICER = ((overall cost of FS
arm—overall cost of SOC arm)/(no. of complications in
FS arm—no. of complications in SOC arm)).
The variation in costs between the treatment arms will
be calculated individually for each patient based on their
time in the operating theatre (including returns to
theatre), their length of stay within each ward type, their
number of hospital visits in the immediate post-
operative period (both planned and unplanned), and the
cost of materials (including those required to administer
FS).
Sample size
As this is a pilot study, no formal power/sample size cal-
culation based on clinical data is given. For this study,
the two main outcomes of interest are to determine ac-
curate estimates of the rate of recruitment (being the
number of patients recruited relative to the number eli-
gible) and to collect sufficient clinical data to accurately
estimate a sample size for a future study. It is estimated
that over the study period, approximately 50 patients
will be recruited at rate of 30%. Based on this, 50 pa-
tients (25 in each arm) will produce a standard error of
approximately 6.5% and a 95% confidence interval of ap-
proximately (17–43%) will be obtained. With respect to
surgical complication rate, being the clinical outcome of
current greatest interest, even if a response rate of 50%
is observed, then a 95% confidence interval of (0.36,
0.64) will be observed which provides sufficient precision
for a future sample size.
Recruitment
Patients eligible for the DEFeND trial will be screened
through outpatient clinics and weekly Head and Neck
Multidisciplinary Team meetings. The steps that will be
completed on all patients to ensure they meet enrolment
criteria include the following:
1. Clinical examination
2. Detailed medical history including previous
treatment/surgery to the head and neck
3. Clinical decision to offer a lateral neck dissection
Screening will be performed upon a patient’s possible
eligibility for the study as above and will be documented
in a secure online ‘Screening log”’ managed by the Liver-
pool Cancer Trials Unit (LCTU). There are no restric-
tions regarding concomitant care or interventions
during the trial.
Eligible patients should be approached within the out-
patient setting and provided with a full explanation of
the trial. The patient should also receive an up to date
version of the Patient Information Sheet (PIS) (see Add-
itional file 2). Once the patient has had the opportunity
to read the PIS and ask any questions, they may consent
to the trial (see Additional file 3). The removal of a (24
Table 3 Common head and neck/general complications conformed to the Clavien-Dindo classification (Continued)
Post-operative complication Description of severity Clavien-Dindo grade
dysfunction
Pneumothorax/haemothorax Small pneumothorax managed without a chest drain I
Pneumothorax/Haemothorax without respiratory failure requiring chest drain IIIa
Evidence of respiratory failure or any other organ dysfunction IV (a or b depending on
organ dysfunction)
Pulmonary embolism Small PE without evidence of respiratory failure managed with
anticoagulation only
II
Evidence of respiratory failure or any other organ dysfunction IV (a or b depending on
organ dysfunction)
Deep vein thrombosis Managed with anticoagulation only II
Need for endovascular intervention including filters not under GA IIIa
Need for endovascular intervention or surgical thrombectomy under GA IIIb
Lower respiratory tract infection
(including aspiration)
Managed with physiotherapy only I
Managed with antibiotics II
Evidence of respiratory failure or any other organ dysfunction IV (a or b depending on
organ dysfunction)
GA general anaesthesia
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h) cool-off period prior to signing the consent form has
been agreed by the REC; the patient is simply given as
much time as they deem necessary. The rationale for
such an approach was to reduce patient burden; the
recruiting hospitals are tertiary centres with many
patients travel long distances to attend appointments.
Harmonising the research process with standard clinical
care appointments seeks to avoid extra hospital visits,
allowing patients the option to provide study consent on
the day of being approached.
The DEFeND trial requires that completed consent
forms are securely uploaded to the LCTU’s online portal
with the patient’s identifiable data still visible. The con-
sent forms will be checked by two independent members
of the central trial team. Once these checks have taken
place and the consent considered valid, the uploaded
document will be permanently deleted from the portal.
Any further reference to the consent will need to be per-
formed by accessing the original hard copy stored at the
site in the patient’s medical records.
Allocation
Randomisation lists will be computer-generated by the
statistician prior to the recruitment of the first patient.
Patients will be randomised using a 1:1 ratio. Lists will
be produced based on the principle of randomly
permuted blocks with random block sizes of 2 and 4. Pa-
tients will only be stratified according to the hospital in
which they receive their treatment.
The process of randomisation will be undertaken pre-
operatively using the “Treatment Allocation RanDomIsa-
tion System” (TARDIS) software version 3.8. This
software has been developed by the LCTU. The alloca-
tion will be concealed to everyone including the person
performing the randomisation. Once randomisation has
been performed, the surgeon caring for the patient will
receive an automated email which contains a link to re-
veal the allocation. Once the patient has undergone their
neck dissection immediately prior to the point of wound
closure, the surgeon will open the link and login to
TARDIS to reveal the allocation. The exact time and
date this occurs will be recorded and cross-referenced
against the start and finish times of surgery as a quality
assurance step to minimise performance bias. The ran-
domisation process can be performed either centrally or
at the site once the eligibility criteria have been entered
and signed off by the Principal Investigator.
As part of the blinding strategy, any clinicians who will
be assessing study outcomes must leave theatre prior to
the revealing of treatment allocation. They must not re-
turn until the theatre has been cleared of any evidence
of FS usage. The surgeon administering the FS will not
be allowed to assess study outcomes for the patient and
must delegate this responsibility to a suitable colleague.
Blinding
Patients, clinical outcome assessors, ward staff and re-
search staff both centrally and at the site will be blinded
to the allocation. Only members of the surgical team
present in the theatre when the allocation is revealed
will know which treatment arm the patient has been al-
located to. These individuals are not permitted to inform
colleagues or assess trial outcomes. The operation note,
medical case notes and any other documentation that
leaves the operating theatre will not state the allocation.
The effectiveness of this blinding strategy will be
assessed using blinding indices.
The patient will be unblinded if they suffer a serious
adverse event and knowledge of the allocation is re-
quired for the ongoing medical management of the con-
dition. It is unlikely that this trial will require unblinding
as the FS is administered only once in the theatre envir-
onment. A severe hypersensitivity reaction, air embolism
or transmission of an infective agent constitute a serious
adverse event. If they occur, severe hypersensitivity and
air embolism would be anticipated to occur during or
immediately after administration in the theatre setting.
Staff caring for the patient at this time will not be
blinded, so there will not be a delay in diagnosis and
emergency management.
In the event that the patient is diagnosed with an in-
fectious disease that was not diagnosed pre-operatively,
they will be unblinded. Based on the ‘Serious Hazards of
Transfusion’ 2017 annual report [24], the following in-
fectious diseases are known to have been transmitted via
blood products in the UK:
1. Hepatitis A, B, C or E
2. Human immunodeficiency virus (HIV)
3. Parvovirus (B19)
4. Cytomegalovirus (CMV)
5. Human T cell lymphotropic virus (HTLV) types I
and II
6. Malaria
7. Variant Creutzfeldt-Jakob Disease (vCJD) or any
other prion disease
If the patient is newly diagnosed with any of the above
infectious diseases, they will be unblinded and immedi-
ately referred to the appropriate medical specialists for
treatment.
Data management
Data is entered directly into electronic case report forms
(eCRF) by research teams at the site using MACRO v4
database software. Delegated staff who have undertaken
training to use the software and submitted their current
curriculum vitae (signed and dated) and GCP certificate
(dated in the last 3 years) will be given access to log in.
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Site staff are expected to input data directly into the
eCRF within the clinical environment and in real time.
MACRO v4 has been programmed to calculate the rate
of wound drainage (millilitres per hour). If the rate falls
below 1.25ml/h, MACRO v4 will recommend removal
of the drain in keeping with the protocol. This process
will only work if data is entered in real time.
Electronic versions of the patient-reported question-
naires will be stored on the LCTU’s portal. Research
staff at the site will have individual logins to access this
documentation. It is expected that sites will download
the questionnaires and hand them to patients for com-
pletion at specific time points as stipulated in the proto-
col. It is also expected that the responses will be
transcribed to the eCRF on the same day as the patient
completes them.
To ensure the database is only updated or amended by
authorised individuals, the data entry system requires
users to have a username and password, to be entered at
the start of each data entry session.
Users should log out of the data entry system each
time they leave their work station unattended. Each
computer station should be set to revert to a password-
protected screen saver mode when left idle for 10 min.
Individuals should only work under their own user-
name and should not log anyone else onto the system.
The MACRO database package has several methods
built in to maximise security:
 Each password must contain between 6 and 15
characters, including lower and upper case letters
and at least 1 number.
 If left idle for 20 min MACRO automatically locks
out the user, who must then re-enter their password
to regain access to the database.
MACRO records any changes made to data in the
system, and all user activity is logged. For a particular
question, the audit trails consist of a chronological rec-
ord of the status, response value, warning messages and
overrule reasons, reasons for change, comments and
lock status.
Whenever any of these items are changed, a record is
kept of the date and time, and the username of whoever
made the change. Users with appropriate permission
have access to view audit trails; however, no-one is able
to change or delete an audit trail. The audit trail allows
the LCTU to monitor the quality of individual team
members’ data input and highlight training needs if con-
sistent errors are found.
Statistical methods
The primary analysis will be carried out on the full data
set and will be based on the intention to treat principle,
retaining patients in their initially randomised groups ir-
respective of any protocol violations.
Missing data are expected to be limited, and final ana-
lyses are planned to be carried out on a complete case
basis. If substantial missing data (> 10%) are observed in
either a study outcome or key prognostic covariate, then
multiple imputation using chained equations will be
applied.
There are no formal comparisons of treatment groups,
and therefore, no levels of significance against which hy-
potheses will be tested. As a guide however, all results
will be reported using nominal 95% confidence intervals.
As this is an external pilot study, all data analyses shall
take the form of descriptive statistics. Continuous data
shall be summarised as medians with associated inter-
quartile ranges and categorical data shall be summarised
as frequencies of counts and associated percentages.
In terms of clinical outcomes, aside from descriptive
statistics, informal comparisons between allocated
groups will be made using the difference in means for
continuous covariates and differences in rates for cat-
egorical covariates.
Data monitoring
Formal interim analyses of the accumulating data will be
performed at 6 monthly intervals after the recruitment
of the first patient. A formal Independent Data Monitor-
ing and Safety Committee (IDMSC) will not be con-
vened. In keeping with the guidance outlined in the
document ‘Guideline in Data Monitoring Committees’
published by the Committee for Medicinal Products for
Human Use [25], it is thought that an IDMSC is not
required. This is because patients will be treated for a
very short period of time (single administration during
surgery) and fibrin sealants are well characterised and
already widely used within healthcare. Although there
are potential risks to patients, these are incredibly rare
and known.
The independent members of the TSC (chairperson,
expert, statistician) will take responsibility for reviewing
all interim safety data. The independent members will
be asked to give advice on whether the accumulated data
from the trial, together with results from other relevant
trials, justifies continuing recruitment of further patients
or further follow-up. Given this is a pilot/feasibility
study, it is anticipated that the TSC will only recom-
mend termination on grounds of safety.
Safety
Surgical complications and adverse reactions to fibrin
sealant that are Clavien-Dindo grade IV or above (see
Tables 2 and 3) will be the only events reported to assess
safety. As the ‘Clavien-Dindo Classification of Surgical
Complications’ constitutes a primary outcome measure
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for the DEFeND pilot trial, the presence of post-
operative complications along with their grade will be
recorded on the eCRF. All complications related to the
neck dissection surgery and/or use of fibrin sealant that
are Clavien-Dindo grade III-b or below that meet the
definition of serious are exempt from Serious Adverse
Event (SAE) reporting. Such events are ‘expected’ and
should only be recorded in the relevant section of the
eCRF.
Post-operative complications related to either neck
dissection or use of fibrin sealant that are Clavien-Dindo
grade IV or above are ‘unexpected’ for the DEFeND trial.
The LCTU will notify the main REC of all Suspected
Unexpected Serious Adverse Reactions (SUSARs)
occurring during the study according to the following
timelines; fatal and life-threatening within 7 days of noti-
fication and non-life-threatening within 15 days. All in-
vestigators will be informed of all SUSARs occurring
throughout the study.
Site staff (with the exception of the surgical team) will
be blinded; therefore, the SAE reporting form will not
state which arm the patient has been randomised to. For
the purposes of SAE reporting, it should be assumed
that the patient was randomised to receive fibrin sealant
(i.e. interventional arm). Causality should be assigned to
the following:
1. Anaesthetic
2. Generality of surgery (including surgical airway,
primary tumour resection)
3. Neck dissection surgery
4. Use of fibrin sealant
Pregnancy is listed as an exclusion criterion for entry
to the DEFeND trial. In the event of a patient becoming
pregnant after recruitment to the trial, this fact should
be reported in the same way as an SAE. The guiding
principles in this event are as follows:
1. If the patient has not yet received treatment, or
completed treatment, the patient may be withdrawn
from the trial.
2. Once treatment is complete, i.e. the patient is in
follow-up phase, it may well be possible to retain
the patient to the conclusion of the trial.
3. A decision will be made in the best interests of the
patient between the treating clinician and the Chief
Investigator as to retention in the trial and any
continuing cancer therapy.
Dissemination policy
The results of the pilot trial will be reported in peer-
reviewed journals, in a report to the funder and as a lay
summary to participants. We will apply authorship
criteria established by the International Committee of
Medical Journal Editors.
Discussion
The key challenges that are anticipated in the DEFeND
external pilot trial are common to many surgical RCTs
and can be encapsulated within three broad headings:
barriers to recruitment, complexity of the intervention
and adherence to the protocol.
Barriers to recruitment
Kaur et al. described the barriers to recruitment for sur-
gical trials in Head and Neck Oncology by conducting a
survey of investigators from three of the earliest trials
within the National Institute of Health Research (NIHR)
portfolio [15]. Given that UK-based surgical trials in
Head and Neck were in their relative infancy, all of these
trials faced challenges with recruitment. The most com-
monly perceived barriers were lack of equipoise amongst
patients demonstrated by a refusal to participate due to
an expressed treatment preference, patient consent re-
fusal owing to aversion to randomisation, excess com-
plexity and amount of information provided to patients
and lack of time in the clinic. All of these barriers are re-
lated to how investigators communicate the premise of
the trial to patients. The ‘Merseyside Head and Neck
Cancer Patient Research Forum’ is comprised of patients
who have undergone treatment for head and neck can-
cer and was setup specifically to facilitate patient and
public involvement in research. The PIS and informed
consent forms (see Additional files 2 and 3) have been
successfully passed through the forum to ensure they are
easily understood while delivering sufficient detail and
conveying equipoise.
Given the increase in complexity of the UK clinical
trials, trials with overlapping inclusion criteria might also
present a barrier to recruitment. Aintree University
Hospital has a very research active Head and Neck
Surgery Department, and it is possible that patients will
be offered more than one study to participate in. This
may result in patients suffering from excessive research
burden resulting in consent refusal across the board. A
predetermined hierarchy of recruitment has been de-
cided amongst all the CI/PIs of the competing studies to
enable investigators to minimise the risk of research
burden.
The pilot and feasibility outcomes in the DEFeND
external pilot trial will allow an in-depth analysis of
recruitment and identify any further barriers. This
will inform the design and execution of the phase III
trial and attempts to mitigate these barriers will be
made.
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Complexity of the intervention
One of the differences between surgical trials and
pharmacological trials is the complexity of the interven-
tion. Surgical interventions are multi-faceted and depend
on the performance of the wider healthcare team in
addition to the skill, experience and decision making of
the operating surgeon. Outcomes in the DEFeND study
are dependent on the perioperative management of pa-
tients; the neck dissection surgery itself; the need for
other synchronous surgical procedures e.g. resection of
the primary tumour; and the intervention itself. As the
administration of FS is considered SOC, it is expected
that randomisation will balance the variables equally
across both arms.
In order that surgeons administer FS in a standardised
way, a video has been produced and laminated sheets
hung up in operating theatres providing temporal detail
of the protocol. Many surgeons will be experienced at
administering FS, but for those that are not ‘ad hoc’,
training will be available. It is recognised that surgeon
level performance will vary and as such the ideal stand-
ard procedure will not be replicated on each occasion.
Currently, there are no requirements for surgeons to
perform the surgery/administer FS a minimum number
of times or achieve a predetermined standard. This is
primarily to reflect the ‘real-world’ nature of the study. If
the impact of the learning curve is clearly demonstrated
in the pilot data, then surgeons acquiring a certain level
of expertise to participate in the phase III trial will be
considered.
Adherence to the protocol
While every effort has been made to harmonise the
protocol with standard clinical/research practice, there
will inevitably be some challenges with adherence.
i) The use of eCRF is new to both research sites and
requires real-time data entry. This will require
training and logistical planning by sites to ensure
there are sufficient research staff available (includ-
ing weekend cover).
ii) The allocation needs to be revealed at a specific
time point during surgery. This requires surgeons
to access their email, login to the randomisation
software (TARDIS) and reveal the allocation. To
minimise performance bias, the allocation must not
be revealed too early; this will be monitored by
recording the date and time the allocation is
revealed and cross-referencing this with the start
and finish times of surgery.
iii) The blinding strategy may be difficult to enforce
within busy clinical practice. The surgeons present
in theatre at the time of the allocation reveal are
not allowed to assess trial outcomes. In standard
clinical practice, it is routine for the operating
surgeon to review their patient post-operatively;
eliminating their influence on outcomes including
the patient’s perception of outcomes will be diffi-
cult. If it is known that a particular surgeon will be
reviewing the patient post-operatively, they will be
asked to vacate theatre at the time of the reveal.
iv) Patients are required to attend two planned follow-
up appointments after surgery. The first at 7–14
days to coincide with the removal of skin clips and
the second at 4–6 weeks to coincide with the first
routine clinic appointment. It is possible that this
schedule will clash with some follow-up arrange-
ments and necessitate patients making extra visits.
A modest financial refund for travelling expenses
will be offered to patients for any extra visits.
Progression to phase III trial
This initial study aims to inform the design, feasibility
and conduct of a future phase III surgical trial. The deci-
sion to progress to this future trial will be based on vari-
ables such as recruitment rate, safety of intervention,
sample size estimation and ongoing surgical equipoise. It
is anticipated that further amendments to the protocol
will be required to fine tune the trial design based on
the outcomes of this external pilot trial and feedback
from sites (both research staff and surgeons). All these
issues will be discussed by the TSC once the external
pilot trial has closed and a decision to progress to a
phase III trial made.
Trial status
Recruitment started on November 06, 2018, and is on
target to achieve at the pre-specified sample size in the
scheduled 12 months. The interventions appear to be ac-
ceptable to potential participants, and approximately
50% of those who have been approached to take part
have given written consent. The protocol being used is
version 2.0 dated June 27, 2018.
Supplementary information
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1186/s40814-020-00618-w.
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